# This Study is Done in Patients With Plaque Psoriasis and Tests How Well They Tolerate BI 730357 and How Effective it is

> **NCT03635099** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 274 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Placebo (fasted)
- **DRUG:** BI 25 mg (fasted)
- **DRUG:** BI 50 mg (fasted)
- **DRUG:** BI 100 mg (fasted)
- **DRUG:** BI 200 mg (fasted)
- **DRUG:** Placebo (fed)
- **DRUG:** BI 400 mg once daily (fed)
- **DRUG:** BI 200 mg twice daily, 400 mg total (fed)

## Key facts

- **NCT ID:** NCT03635099
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-17
- **Primary completion:** 2021-05-06
- **Final completion:** 2021-05-26
- **Target enrollment:** 274 (ACTUAL)
- **Last updated:** 2022-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03635099

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03635099, "This Study is Done in Patients With Plaque Psoriasis and Tests How Well They Tolerate BI 730357 and How Effective it is". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03635099. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*